PolyPid Ltd. (PYPD) Reports Q1 Loss of $0.28/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 10, 2023 7:00 AM EDTSubmitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX100Â for Prevention of Abdominal Colorectal Surgical Site Infections; Recruitment Expected to Resume Imminently
Received Advice from the Swedish Medical Products Agency Consistent with Feedback Received from the FDA
Completed a Series of Transactions to Further Solidify Financial Position and Extend Cash Runway to Late in Q1 2024
... More